BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Swedish Orphan Biovitrum AB (publ) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Swedish Orphan Biovitrum AB (publ
 )'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05681351-1044@assetmemo.bio
DTSTAMP:20261121T005037Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT05681351)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Severe Hypertriglyceridemia.\
 nStudy: CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutan
 eously to Participants With Severe Hypertriglyceridemia (SHTG)\nEstimated 
 primary completion: March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/olezarsen#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05681351
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05185843-1044@assetmemo.bio
DTSTAMP:20261121T005037Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT05185843)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Familial Chylomicronemia Synd
 rome.\nStudy: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) A
 dministered to Adults With Familial Chylomicronemia Syndrome (FCS) Previou
 sly Treated With Volanesorsen\nEstimated primary completion: June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/olezarsen#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05185843
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05809531-907@assetmemo.bio
DTSTAMP:20261121T005037Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Empaveli (Pegcetacoplan): Phase 3 readout est. (NCT05809531)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 3.\nStudy: An Open-Label\, Non
 randomized\, Multicenter Extension Study to Evaluate the Long-term Safety 
 and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Im
 mune-Complex Membranoproliferative Glomerulonephritis\nEstimated primary c
 ompletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pegcetacoplan#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05809531
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05130450-1044@assetmemo.bio
DTSTAMP:20261121T005037Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT05130450)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Familial Chylomicronemia Synd
 rome.\nStudy: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) i
 n Participants With Familial Chylomicronemia Syndrome (FCS)\nEstimated pri
 mary completion: February 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/olezarsen#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05130450
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04901936-907@assetmemo.bio
DTSTAMP:20261121T005037Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Empaveli (Pegcetacoplan): Phase 2 readout est. (NCT04901936)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 2\, Paroxysmal Nocturnal Hemog
 lobinuria.\nStudy: A Study of Pegcetacoplan in Pediatric Patients With Par
 oxysmal Nocturnal Hemoglobinuria (PNH)\nEstimated primary completion: Dece
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pegcetacop
 lan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04901936
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07727538-1044@assetmemo.bio
DTSTAMP:20261121T005037Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT07727538)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Familial Chylomicronemia Synd
 rome.\nStudy: A Study of Olezarsen for the Treatment of Familial Chylomicr
 onemia Syndrome (FCS) in Pediatric Participants\nEstimated primary complet
 ion: August 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ole
 zarsen#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07727538
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07898774-907@assetmemo.bio
DTSTAMP:20261121T005037Z
DTSTART;VALUE=DATE:20310117
DTEND;VALUE=DATE:20310118
SUMMARY:Empaveli (Pegcetacoplan): Phase 3 readout est. (NCT07898774)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 3.\nStudy: A Study to Assess t
 he Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3
 G or Primary IC-MPGN in Kidney Transplant Recipients\nEstimated primary co
 mpletion: 17 January 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pegcetacoplan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07898774
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
